The clinical trial is sponsored by the Chinese PLA General Hospital and aims to evaluate the safety and efficacy of autologous CD19-targeting STAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL). Given the increasing prevalence of B-NHL and the limitations of existing CAR-T therapies, this innovative approach could capture significant market share if proven effective. The trial's unique mechanism of action, which combines elements of CAR and TCR therapies, positions it competitively against established therapies. The trial is currently recruiting, with an estimated completion date in December 2025, indicating a potential for early market entry if successful. Stakeholders should monitor the trial closely for developments that could influence market dynamics and investment opportunities.